| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/BF00197522 |
| P698 | PubMed publication ID | 7716709 |
| P2093 | author name string | M F Gourley | |
| P2860 | cites work | Contribution of renal biopsy data in predicting outcome in lupus nephritis. Analysis of 116 patients | Q30630146 |
| Multiple complications of the antiphospholipid syndrome with apparent response to aspirin therapy | Q33368258 | ||
| Antiphospholipid Thrombosis: Clinical Course after the First Thrombotic Event in 70 Patients | Q33369688 | ||
| Intermittent cyclophosphamide for the treatment of autoimmune thrombocytopenia in systemic lupus erythematosus | Q33405430 | ||
| The comparison of gammaglobulin to steroids in treating adult immune thrombocytopenia. An interim analysis | Q33434613 | ||
| The association between the lupus anticoagulant and cerebral infarction in systemic lupus erythematosus | Q33446426 | ||
| Splenectomy for cytopenias associated with systemic lupus erythematosus. | Q33450515 | ||
| Danazol for the Treatment of Refractory Autoimmune Thrombocytopenia in Systemic Lupus Erythematosus | Q33450721 | ||
| Results of treatment in immune thrombocytopenia | Q33455760 | ||
| Splenectomy in systemic lupus erythematosis | Q33455961 | ||
| Splenectomy does not cure the thrombocytopenia of systemic lupus erythematosus | Q33459214 | ||
| Which patients with antiphospholipid antibody should be treated and how? | Q33493823 | ||
| Action of chloroquine phosphate in rheumatoid arthritis. 1. Immunosuppressive effect | Q33568583 | ||
| Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis | Q34244145 | ||
| Fluorescent light photosensitivity in patients with systemic lupus erythematosus | Q34486537 | ||
| The incidence and prognosis of central nervous system disease in systemic lupus erythematosus | Q35965008 | ||
| Predicting renal outcomes in severe lupus nephritis: contributions of clinical and histologic data | Q36748174 | ||
| Treatment of systemic lupus erythematosus: which options do we have for therapy regimens? | Q36840264 | ||
| Fetal survival after prednisone suppression of maternal lupus-anticoagulant | Q72553985 | ||
| Standardized ultraviolet-A exposure provokes skin reaction in systemic lupus erythematosus | Q72676765 | ||
| Risk for sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy | Q72849010 | ||
| Effects of oral administration of type II collagen on rheumatoid arthritis | Q72936919 | ||
| Intravenous immunoglobulin treatment of pregnant patients with recurrent pregnancy losses associated with antiphospholipid antibodies | Q72951395 | ||
| Long-term outcome of systemic lupus erythematosus in childhood. What is the prognosis? | Q36899712 | ||
| Lymphokine receptor-directed therapy: a model for immune intervention in leukemia, autoimmunity, and immunodeficiency | Q37433193 | ||
| Treatment of cutaneous lesions in patients with lupus erythematosus | Q37932273 | ||
| The treatment of lupus nephritis | Q39749422 | ||
| Interferons. New additions and indications for use. | Q40485005 | ||
| Treatment of Diffuse Proliferative Lupus Nephritis with Prednisone and Combined Prednisone and Cyclophosphamide | Q40691464 | ||
| Treatment of murine lupus with anti-CD4 monoclonal antibodies | Q40708868 | ||
| Extracorporeal photochemotherapy induces the production of tumor necrosis factor-alpha by monocytes: implications for the treatment of cutaneous T-cell lymphoma and systemic sclerosis | Q40734336 | ||
| Reduction by Granulocyte Colony-Stimulating Factor of Fever and Neutropenia Induced by Chemotherapy in Patients with Small-Cell Lung Cancer | Q40746556 | ||
| Pneumococcal infections in splenectomized children are preventable | Q40749720 | ||
| Biology of monoclonal antibodies in tumor therapy. | Q40789587 | ||
| Is aggressive therapy effective for lupus? | Q40837384 | ||
| Is "aggressive" therapy necessary for systemic lupus erythematosus? | Q40837390 | ||
| Plasmapheresis and subsequent pulse cyclophosphamide versus pulse cyclophosphamide alone in severe lupus: design of the LPSG trial. Lupus Plasmapheresis Study Group (LPSG). | Q41187058 | ||
| Immunosuppressive potential of antimalarials | Q41585528 | ||
| Ciclosporin plus steroids versus steroids alone in the treatment of lupus nephritis | Q41777810 | ||
| Antigen presentation by human monocytes: evidence for stimulant processing and requirement for interleukin 1. | Q41920813 | ||
| Dose refinements in long-term therapy of rheumatoid arthritis with antimalarials | Q41921005 | ||
| Ophthalmologic considerations and testing in patients receiving long-term antimalarial therapy | Q41921017 | ||
| The effect of immunosuppressive and anti-inflammatory drugs on monocyte function in vitro | Q41929911 | ||
| Treatment of cutaneous lupus erythematosus with acitretin and hydroxychloroquine | Q41939243 | ||
| Pregnancy outcome following first trimester exposure to chloroquine | Q41942091 | ||
| A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus | Q41942545 | ||
| Cholesterol-lowering effect of hydroxychloroquine in patients with rheumatic disease: reversal of deleterious effects of steroids on lipids | Q41943371 | ||
| Extracorporeal photochemotherapy for the treatment of systemic lupus erythematosus. A pilot study | Q43489163 | ||
| Systemic lupus erythematosus in a child receiving long-term interferon therapy | Q44014583 | ||
| Continuous removal of anti-DNA antibody, using a new extracorporeal immunoadsorption system, in patients with systemic lupus erythematosus | Q44746983 | ||
| Clinical and immunologic effects of monthly administration of intravenous cyclophosphamide in severe systemic lupus erythematosus | Q44839857 | ||
| Ciclosporin in the treatment of lupus nephritis | Q45350416 | ||
| Treatment of murine lupus with monoclonal antibody to L3T4. II. Effects on immunohistopathology of thymus, spleen, and lymph node. | Q45943482 | ||
| Heparin therapy for pregnant women with lupus anticoagulant or anticardiolipin antibodies. | Q46728540 | ||
| Pulse Cyclophosphamide for Severe Neuropsychiatric Lupus | Q48615269 | ||
| Double-Blind Pilot Trial of Oral Tolerization with Myelin Antigens in Multiple Sclerosis | Q50127386 | ||
| The economic impact of treatment of severe lupus nephritis with prednisone and intravenous cyclophosphamide. | Q50601618 | ||
| Antibody to cardiolipin, lupus anticoagulant, and fetal death. | Q52428260 | ||
| Approach to the study of the role of sex hormones in autoimmunity | Q66970920 | ||
| Treatment of lupus nephritis with CD5 PLUS, an immunoconjugate of an anti-CD5 monoclonal antibody and ricin A chain | Q67538882 | ||
| Lupus-like autoimmune disease induced by interferon therapy for myeloproliferative disorders | Q67543237 | ||
| Role of pathology indices in the management of severe lupus glomerulonephritis. Lupus Nephritis Collaborative Study Group | Q67560104 | ||
| Clinical effect of recombinant human granulocyte colony-stimulating factor (rhG-CSF) on various types of neutropenia including cyclic neutropenia | Q67709887 | ||
| Hypertension and renal disease in systemic lupus erythematosus | Q67806367 | ||
| Long-term preservation of renal function in patients with lupus nephritis receiving treatment that includes cyclophosphamide versus those treated with prednisone only | Q67925070 | ||
| Kidney biopsy in systemic lupus erythematosus. II. Survival analyses according to biopsy results | Q68028228 | ||
| A controlled trial of plasmapheresis therapy in severe lupus nephritis. The Lupus Nephritis Collaborative Study Group | Q68102206 | ||
| Transverse myelitis in systemic lupus erythematosus--the effect of IV pulse methylprednisolone and cyclophosphamide | Q68112954 | ||
| Experience with 19-nortestosterone in the therapy of systemic lupus erythematosus: worsened disease after treatment with 19-nortestosterone in men and lack of improvement in women | Q68136500 | ||
| Repeated fetal losses associated with antiphospholipid antibodies: a collaborative randomized trial comparing prednisone with low-dose heparin treatment | Q68139494 | ||
| Treatment of severe systemic lupus erythematosus with anti-CD4 monoclonal antibody | Q68326745 | ||
| Inhibition of autoimmune disease in a murine model of systemic lupus erythematosus induced by exposure to syngeneic photoinactivated lymphocytes | Q68693969 | ||
| Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs | Q68859513 | ||
| Murine models of systemic lupus erythematosus | Q69894910 | ||
| Prednisone does not prevent recurrent fetal death in women with antiphospholipid antibody | Q69946465 | ||
| Obstetric complications associated with the lupus anticoagulant | Q69970475 | ||
| Controlled studies of oral immunosuppressive drugs in lupus nephritis. A long-term follow-up | Q70261365 | ||
| Second-trimester fetal monitoring and preterm delivery in pregnancies with systemic lupus erythematosus and/or circulating anticoagulant | Q70372396 | ||
| Fluorescent light photosensitivity in patients with systemic lupus erythematosus: comment on the article by Rihner and McGrath | Q70607986 | ||
| Immunosuppressive drug therapy for rheumatic disease | Q70764566 | ||
| Effect of treatment on the evolution of renal abnormalities in lupus nephritis | Q71438057 | ||
| P433 | issue | 2-3 | |
| P304 | page(s) | 281-294 | |
| P577 | publication date | 1994-01-01 | |
| P1433 | published in | Seminars in Immunopathology | Q15724576 |
| P1476 | title | Systemic lupus erythematosus--disease management | |
| P478 | volume | 16 |
| Q78679215 | [Current therapy of lupus nephritis] | cites work | P2860 |
Search more.